NEWTOWN SQUARE, Pa., July 24, 2019 /PRNewswire/ -- "The Trump administration has announced an ambitious plan to change treatment for kidney disease in the United States. President Trump signed an executive order on July 10th directing the Department of Health and Human Services [HHS] to develop policies addressing three goals: reducing the number of patients developing kidney failure, reducing how many Americans get dialysis treatment at dialysis centers, and making more kidneys available for transplant." https://www.nytimes.com/2019/07/10/health/trump-kidney-disease- transplant.html
As a pioneer in the Enteric Dialysis® platform technology, Kibow® Biotech's mission has always been in conjunction with the standard care of therapy. The company's kidney health supplement product was developed to support normal kidney function which may help to slow the progression of kidney function in all stages of Chronic Kidney Disease (CKD) and potentially help a better outcome for dialysis patients worldwide.
Kibow® Biotech Inc is proud to announce that throughout its 22 years of operation, the focus on supporting and maintaining healthy kidney function with probiotics/prebiotics to potentially delay the progression to dialysis is based on its enteric toxin reduction platform technology termed "Enteric Dialysis®". Since 2005, Kibow® has been a pioneer and leader in the presently marketed kidney health supplement product, Renadyl™*.
Kibow® has been participating and exhibiting at various nephrology and medical professional annual meetings, like the American Society of Nephrology (ASN), National Kidney Foundation (NKF), American Association of Kidney Patients (AAKP), World Congress of Nephrology (WCN) and several other professional medical conferences since 2005. Kibow® Biotech's participation in these events is intended to educate nephrology and all other medical professionals about the emerging importance and crucial role of probiotics/prebiotics, gut-kidney connection, dysbiosis, and modulation of the Gut Microbiome with its innovative "Enteric Dialysis®" platform technology.
Kibow® is committed to improving kidney health in patients with kidney problems, not only for Americans but in all countries worldwide. Although marketed and sold as a dietary supplement product, Renadyl™ is the first and only kidney health supplement developed and formulated based on clinical results that utilizes Kibow® Biotech's patented and revolutionary "Enteric Dialysis®" technology. For more detailed R&D and peer reviewed scientific/clinical journal articles, please refer to: https://kibowbiotech.com/rd/ and https://kibowbiotech.com/journal-publications/.
Even before President Trump's announcement, Kibow® Biotech has been taking steps to reach and improve more patients' lives by diversifying Renadyl™ from health supplement to a novel live biotherapeutic drug product (micro-organisms) and obtaining approval as a new drug product.. As an FDA-approved human drug, Renadyl™ will be able to be marketed based on specific health benefit claims which should lead to greater acceptance by healthcare professionals.
It will also pave the way for its medical reimbursement and could result in lower co-payment cost – both from private insurers and federal Medicare/Medicaid authorities. In addition to maintaining normal kidney function and slowing the progression of kidney disease, the goal would be to delay the need for expensive, physically and mentally taxing dialysis therapy. As a LBP drug product, Renadyl™ may also be potentially useful in reducing the duration or frequency of dialysis with significantly improved quality of life and help save several billions of dollars spent not only in the USA but worldwide.
Kibow® has already initiated the Pre-Investigational New Drug (IND) application and subsequently will continue with the IND application process with US FDA's Center for Biological Evaluation Research (CBER) for its improved Renadyl™ Probiotics/Prebiotics formulation as a LBP drug product. In order to gain drug approval, Kibow will be required to perform well-controlled, randomized clinical efficacy and safety testing. Kibow® has planned the "Kibow® Hope Study", a multisite, Randomized Controlled Trial (RCT) on CKD patients in stages III and IV. The proposed Kibow® Hope RCT study will involve about 600 patients spread over 20 to 25 hospitals/clinics. The company intends to perform this multi-site RCT with the collaboration from highly accomplished clinical study investigators within the USA at their respective clinics/institutions/hospitals. Similar clinical trials will also be proposed and undertaken in several other countries.
Furthermore, it is known that 40% of CKD patients also suffer from gout due to higher levels of uric acid. Kibow® has developed a dietary supplement product which acts to maintain normal uric acid levels in blood, Animal studies have shown that the product reduces uric acid concentrations and also stabilizes blood pressure -https://www.ncbi.nlm.nih.gov/pubmed/30142173 . The company is in the process of performing open label Institutional Review Board (IRB) approved clinical studies monitoring similar endpoints in human subjects. Subsequently, Kibow® plans to explore the potential of another IND process with US FDA/CBER and seek FDA approval for gout/hyperuricemia applications. All Kibow® products have been developed based on selection of specific probiotic strains for CKD and Gout applications respectively.
Dr. Ranganathan, the founder and key R&D scientist of Kibow® states,
"Use of various probiotic and prebiotic (fiber) products as dietary supplements are gaining greater public interest in children and adults for digestive, immune, and gut health. They are Generally Recognized As Safe (GRAS) by the US FDA. Renadyl™ as a kidney health supplement was introduced to US consumers in 2010 and subsequently exported to various oversea countries. No serious adverse events have been notified either to the company or US FDA after human use of Renadyl™ during the past nine years. This market experience provide support for the safety of Renadyl™ for kidney health applications. Kibow® has been on the forefront of having developed and scientifically validated the concept of "ENTERIC DIALYSIS®" with its flagship product Renadyl™. Medical professionals and a large base of educated customers are always on the lookout and ready to adapt to a well-researched, Scientifically-based natural treatment"
Dr. Ranganathan's invited commentary titled Reality of "Enteric Dialysis®" with Probiotics and Prebiotics to Delay the Need of Conventional Dialysis published in the Journal of Nephrology & Therapeutics in 2018 can be accessed in the link - https://www.omicsonline.org/open-access/reality-of-34enteric-dialysis-17434-with- probiotics-and-prebiotics-to-delay-the-need-of-conventional-dialysis-2161-0959- 1000319-105040.html.
Further updates will be made available during the upcoming American Society of Nephrology Kidney Week Meeting (November 5-10, 2019) https://www.asn- online.org/education/kidney week/ in Washington DC where Kibow® has been participating as an exhibitor for the past 15 years.
About Kibow® Biotech: Kibow® Biotech was founded on October 1st, 1997 at the University City Science Center incubator in Philadelphia, PA. The company specializes in research, development, and commercialization of patented and proprietary probiotic/prebiotic supplements. Kibow® Biotech's primary mission is to offer affordable, easily administered, and readily available healthcare supplements that support kidney and gut health. The company's flagship product, Renadyl™*, is currently marketed in the U.S.A., Canada, India, Mexico, and Malaysia. It will progressively be made available worldwide according to individual countries' governmental rules and regulatory authorities.
About Uremic Toxin Reduction Platform Technology – also known as "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel because of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/ for cats and dogs with moderate to severe kidney failure) consists of a combination of three highly specific probiotic microbial strains and also prebiotics in a proprietary formulation.
Kidney health supplement that has been clinically tested: Kibow® Biotech is not a pharmaceutical company. Kibow® products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ is not meant to cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to several factors.
These include but are not limited to the possibility that Renadyl™ may not reduce levels of uremic toxins in each individual, due to differences that exist between individuals that cannot be controlled such as genetics and lifestyle factors, as well as environmental factors that would include proper storage of the product and conditions of transport of the product in the chain of commerce. Other factors that could cause or contribute to differences in actual results include, but are not limited to: whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
Investor & Media Contact:Terrence O. Tormey – CEO, Kibow Biotech, Inc. (610) 353-5130 or Email: [email protected]
Advertisement
As a pioneer in the Enteric Dialysis® platform technology, Kibow® Biotech's mission has always been in conjunction with the standard care of therapy. The company's kidney health supplement product was developed to support normal kidney function which may help to slow the progression of kidney function in all stages of Chronic Kidney Disease (CKD) and potentially help a better outcome for dialysis patients worldwide.
Advertisement
Kibow® Biotech Inc is proud to announce that throughout its 22 years of operation, the focus on supporting and maintaining healthy kidney function with probiotics/prebiotics to potentially delay the progression to dialysis is based on its enteric toxin reduction platform technology termed "Enteric Dialysis®". Since 2005, Kibow® has been a pioneer and leader in the presently marketed kidney health supplement product, Renadyl™*.
Kibow® has been participating and exhibiting at various nephrology and medical professional annual meetings, like the American Society of Nephrology (ASN), National Kidney Foundation (NKF), American Association of Kidney Patients (AAKP), World Congress of Nephrology (WCN) and several other professional medical conferences since 2005. Kibow® Biotech's participation in these events is intended to educate nephrology and all other medical professionals about the emerging importance and crucial role of probiotics/prebiotics, gut-kidney connection, dysbiosis, and modulation of the Gut Microbiome with its innovative "Enteric Dialysis®" platform technology.
Kibow® is committed to improving kidney health in patients with kidney problems, not only for Americans but in all countries worldwide. Although marketed and sold as a dietary supplement product, Renadyl™ is the first and only kidney health supplement developed and formulated based on clinical results that utilizes Kibow® Biotech's patented and revolutionary "Enteric Dialysis®" technology. For more detailed R&D and peer reviewed scientific/clinical journal articles, please refer to: https://kibowbiotech.com/rd/ and https://kibowbiotech.com/journal-publications/.
Even before President Trump's announcement, Kibow® Biotech has been taking steps to reach and improve more patients' lives by diversifying Renadyl™ from health supplement to a novel live biotherapeutic drug product (micro-organisms) and obtaining approval as a new drug product.. As an FDA-approved human drug, Renadyl™ will be able to be marketed based on specific health benefit claims which should lead to greater acceptance by healthcare professionals.
It will also pave the way for its medical reimbursement and could result in lower co-payment cost – both from private insurers and federal Medicare/Medicaid authorities. In addition to maintaining normal kidney function and slowing the progression of kidney disease, the goal would be to delay the need for expensive, physically and mentally taxing dialysis therapy. As a LBP drug product, Renadyl™ may also be potentially useful in reducing the duration or frequency of dialysis with significantly improved quality of life and help save several billions of dollars spent not only in the USA but worldwide.
Kibow® has already initiated the Pre-Investigational New Drug (IND) application and subsequently will continue with the IND application process with US FDA's Center for Biological Evaluation Research (CBER) for its improved Renadyl™ Probiotics/Prebiotics formulation as a LBP drug product. In order to gain drug approval, Kibow will be required to perform well-controlled, randomized clinical efficacy and safety testing. Kibow® has planned the "Kibow® Hope Study", a multisite, Randomized Controlled Trial (RCT) on CKD patients in stages III and IV. The proposed Kibow® Hope RCT study will involve about 600 patients spread over 20 to 25 hospitals/clinics. The company intends to perform this multi-site RCT with the collaboration from highly accomplished clinical study investigators within the USA at their respective clinics/institutions/hospitals. Similar clinical trials will also be proposed and undertaken in several other countries.
Furthermore, it is known that 40% of CKD patients also suffer from gout due to higher levels of uric acid. Kibow® has developed a dietary supplement product which acts to maintain normal uric acid levels in blood, Animal studies have shown that the product reduces uric acid concentrations and also stabilizes blood pressure -https://www.ncbi.nlm.nih.gov/pubmed/30142173 . The company is in the process of performing open label Institutional Review Board (IRB) approved clinical studies monitoring similar endpoints in human subjects. Subsequently, Kibow® plans to explore the potential of another IND process with US FDA/CBER and seek FDA approval for gout/hyperuricemia applications. All Kibow® products have been developed based on selection of specific probiotic strains for CKD and Gout applications respectively.
Dr. Ranganathan, the founder and key R&D scientist of Kibow® states,
"Use of various probiotic and prebiotic (fiber) products as dietary supplements are gaining greater public interest in children and adults for digestive, immune, and gut health. They are Generally Recognized As Safe (GRAS) by the US FDA. Renadyl™ as a kidney health supplement was introduced to US consumers in 2010 and subsequently exported to various oversea countries. No serious adverse events have been notified either to the company or US FDA after human use of Renadyl™ during the past nine years. This market experience provide support for the safety of Renadyl™ for kidney health applications. Kibow® has been on the forefront of having developed and scientifically validated the concept of "ENTERIC DIALYSIS®" with its flagship product Renadyl™. Medical professionals and a large base of educated customers are always on the lookout and ready to adapt to a well-researched, Scientifically-based natural treatment"
Dr. Ranganathan's invited commentary titled Reality of "Enteric Dialysis®" with Probiotics and Prebiotics to Delay the Need of Conventional Dialysis published in the Journal of Nephrology & Therapeutics in 2018 can be accessed in the link - https://www.omicsonline.org/open-access/reality-of-34enteric-dialysis-17434-with- probiotics-and-prebiotics-to-delay-the-need-of-conventional-dialysis-2161-0959- 1000319-105040.html.
Further updates will be made available during the upcoming American Society of Nephrology Kidney Week Meeting (November 5-10, 2019) https://www.asn- online.org/education/kidney week/ in Washington DC where Kibow® has been participating as an exhibitor for the past 15 years.
About Kibow® Biotech: Kibow® Biotech was founded on October 1st, 1997 at the University City Science Center incubator in Philadelphia, PA. The company specializes in research, development, and commercialization of patented and proprietary probiotic/prebiotic supplements. Kibow® Biotech's primary mission is to offer affordable, easily administered, and readily available healthcare supplements that support kidney and gut health. The company's flagship product, Renadyl™*, is currently marketed in the U.S.A., Canada, India, Mexico, and Malaysia. It will progressively be made available worldwide according to individual countries' governmental rules and regulatory authorities.
About Uremic Toxin Reduction Platform Technology – also known as "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel because of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/ for cats and dogs with moderate to severe kidney failure) consists of a combination of three highly specific probiotic microbial strains and also prebiotics in a proprietary formulation.
Kidney health supplement that has been clinically tested: Kibow® Biotech is not a pharmaceutical company. Kibow® products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ is not meant to cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to several factors.
These include but are not limited to the possibility that Renadyl™ may not reduce levels of uremic toxins in each individual, due to differences that exist between individuals that cannot be controlled such as genetics and lifestyle factors, as well as environmental factors that would include proper storage of the product and conditions of transport of the product in the chain of commerce. Other factors that could cause or contribute to differences in actual results include, but are not limited to: whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
Investor & Media Contact:Terrence O. Tormey – CEO, Kibow Biotech, Inc. (610) 353-5130 or Email: [email protected]
View original content:http://www.prnewswire.com/news-releases/kibow-biotech-inc-supports-president-trumps-executive-order-to-advance-american-kidney-health-with-expanded-plans-to-develop-live-bio-therapeutic-product-lbp-as-drugs-to-slow-progression-to-dialysis-300889996.html
SOURCE Kibow Biotech, Inc
